Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST‐elevation myocardial infarction: A randomized controlled trial
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16270 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Hanan Ahmed Hassanain und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ain Shams University Specialized Hospital, Cairo, Egypt. Hauptthemen laut MEDLINE: Atherosclerosis, Colchicine, ST Elevation Myocardial Infarction, Ventricular Remodeling. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Aims
Owing to its underlying inflammatory nature, atherosclerotic cardiovascular disease remains the leading global cause of mortality, particularly post‐ST‐elevation myocardial infarction (STEMI), a condition with significant risk for further cardiovascular events and mortality. This study aimed to investigate colchicine's effect on inflammation, cardiac remodelling and atherosclerotic risk in STEMI patients.
Methods
We conducted a randomized controlled study on 88 STEMI patients undergoing percutaneous coronary intervention. Eligible patients were randomly assigned to 1 of 2 groups. The control group received the guideline‐directed medical therapy for STEMI, and the test group received guideline‐directed medical therapy and 0.5 mg colchicine twice daily for 3 months. The soluble suppressor of tumorigenicity (sST2), interleukin‐1β, lipid profile parameters, triglyceride (TG)/high‐density lipoprotein (HDL‐C) ratio levels and left ventricular ejection fraction were evaluated for patients at baseline and the end of the 3 months.
Results
No significant effects were reported for colchicine on sST2, interleukin‐1β levels or left ventricular ejection fraction. Colchicine significantly lowered TG levels vs . controls, 134 (46–353) vs . 176 (72–825) respectively, P = .02, as well as TG/HDL‐C ratio levels, 4.16 (2.75–5.24) vs . 5.11 (3.51–8.33),` respectively, P = .024. sST2 levels of the studied cohort were positively correlated with their TG/HDL‐C ratio levels ( R = .459, P < .001) at the end of follow‐up.
Conclusion
Our study highlights a promising impact of colchicine on atherosclerosis and cardiac remodelling factors in STEMI patients. Colchicine significantly reduced TG levels and TG/HDL‐C ratio and was safe and well tolerated. Larger long‐term studies powered to assess clinical outcomes of remodelling are necessary to confirm its beneficial effects in STEMI. Clinicaltrial.gov registration ID NCT06054100.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ain Shams University Specialized Hospital, Cairo, Egypt.
- Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
- Cardiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Lamia Mohamed El Wakeel, Hazem Khorshid, Marwa Adel Ahmed
Zitieren
APA
Hassanain, H. A., El Wakeel, L. M., Khorshid, H., & Ahmed, M. A. (2025). Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST‐elevation myocardial infarction: A randomized controlled trial. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16270
Vancouver
Hassanain HA, El Wakeel LM, Khorshid H, Ahmed MA. Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST‐elevation myocardial infarction: A randomized controlled trial. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16270
BibTeX
@article{Hassanain2025,
author = {Hassanain, Hanan Ahmed and El Wakeel, Lamia Mohamed and Khorshid, Hazem and Ahmed, Marwa Adel},
title = {Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST‐elevation myocardial infarction: A randomized controlled trial},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16270}
}
EUVIMED